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Abstract 
WENDY ELIZABETH SARRATT: How Can Appreciative Inquiry be Used to Improve 
Cancer Clinical Trials Efficiency?  The UNC Lineberger Case Study  
(Under the direction of Suzanne Hobbs, DrPH) 
Cancer is a leading cause of death world-wide and the number of new cases 
diagnosed annually is expected to double by 2050.  Better treatments are urgently 
needed.  Clinical trials, the gold standard for testing therapies for safety and efficacy, 
are conducted in settings including academic medical centers.  Long-standing 
difficulties with the clinical trials system are exemplified by the slow pace of clinical 
trial activation and low rate of trial completion.   
Descriptive case study research was conducted at the UNC Lineberger 
Comprehensive Cancer Center to explore how Appreciative Inquiry (AI), a 
generative form of organization development, can be used to improve clinical trials 
efficiency.  The literature on clinical trials efficiency, organization development, 
appreciative inquiry, and case study research was reviewed.  The case study 
protocol included six questions for two units of analysis, research coordinators and 
disease team leaders.  A process improvement initiative using AI had been 
completed and documentation was available for analysis.  AI was conducted with the 
disease team leaders and interview notes were analyzed.  Participant observation 
was employed with both groups.   
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Themes and provocative propositions were identified or created.  Changes 
attributable to the use of appreciative inquiry and potential contributions to improved 
efficiency were documented along with limitations, barriers, or obstacles to the use 
of the technique with each group.  Together the case study protocol questions 
described the extent and effect of applying AI with the two groups.   
 A plan for change included six recommendations to advance and sustain 
change towards improving the clinical trials system.  These included presenting the 
case study report to the Protocol Office Executive Committee; initiating a system-
wide application of AI with the CPO; monitoring efficiency metrics and assessing 
impact of AI; assessing other potential AI applications at UNC Lineberger; publishing 
and presenting findings.  Leadership theory and practice will continue to guide 
efforts to create a more efficient cancer clinical trials program. 
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Chapter 1: Background 
Cancer is a leading cause of death world-wide and in the United States (US). 
It is estimated that 1.5 million new cases will be diagnosed and nearly 600,000 
people will die from cancer in 2010.[2]  About one-third of all women and half of all 
men in the US will develop cancer in their lifetimes and the number of new cancer 
cases diagnosed per year is expected to double to nearly 3 million by 2050.[3, 4]  
Better treatments are urgently needed to decrease mortality from cancer.   
Cancer is a group of more than 100 diseases where the cells become 
abnormal and divide without order or control.[5]  Scientific advancements over the 
last decade hold great promise for marked improvements in cancer therapy.[6]  
Clinical trials are the mechanism through which these biomedical advances can be 
translated into treatments for patients and they are considered the gold standard for 
testing the safety and efficacy of novel therapeutics.[6]   
Cancer clinical trials are conducted in many settings including academic 
medical centers.  Cancer centers recognized by the National Cancer Institute (NCI) 
are the centerpiece of the nation’s effort to reduce cancer incidence, morbidity, and 
mortality.  NCI-designated cancer centers initiate their own trials and partner with 
pharmaceutical companies to test new drugs.  Many of these cancer centers are 
based at academic medical institutions and play an important role in the national 
clinical trials system by comparing the effectiveness of treatments already in use, 
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finding the optimal duration and dose of approved drugs, combining therapies 
developed by different pharmaceutical companies, and developing treatments for 
rare cancers.[6]  Academic institutions pursue research questions critical to the 
health of the public that may be lower priority to the pharmaceutical industry.  
The UNC Lineberger Comprehensive Cancer Center (UNC Lineberger) is one 
of 40 NCI-designated comprehensive cancer centers.  The mission of the UNC 
Lineberger is to reduce cancer occurrence and death in North Carolina and across 
the nation through research, treatment, training and outreach.  Established in 1975 
on a strong foundation in the basic sciences, the UNC Lineberger began focusing on 
clinical research in the 1990s.  This growth included a significant increase in the 
number of faculty conducting clinical trials at UNC, accelerating between 2005 and 
2010 with the addition of 17 new clinical research faculty to the existing group of 63.   
Clinical trials conducted at the UNC Lineberger are managed through its 
Oncology Clinical Protocol Office (CPO).  The CPO is comprised of 58 nursing, 
regulatory, and data management staff.  In recent years, clinical guidance has been 
provided to the CPO primarily via a medical director and six disease team leaders.  
A Protocol Office Executive Committee comprised by the Cancer Center Director, 
Associate Director for Clinical Research, Associate Director for Outreach, the CPO 
Medical Director, and the disease team leaders advises the CPO’s management 
staff and adjudicates prioritization of resources and trials.  In 2010, more than 1000 
patients were enrolled to treatment trials through the CPO.  In 2010 the CPO 
managed 148 active trials and had 136 trials in follow up.  About 50% of patients 
accrued to trials in 2010 were enrolled on investigator-initiated trials that were 
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designed and led by UNC faculty, a strategic priority for the center.  Ten additional 
clinical research faculty are expected to be recruited by 2015 and this continuing 
growth brings increasing leadership and management challenges. 
A primary goal of conducting clinical trials is to make safe, effective new 
therapies available to patients as quickly as possible.  Key to this is minimizing the 
time that elapses between the creation of an idea by an investigator and the 
enrollment of the first patient on the trial, known as time to activation. Recent 
national analyses have shown that time to activation is often more than two years 
long, during which time the concept may lose relevancy given the rapid pace at 
which new basic or preclinical scientific findings are made.[7]  
Another key to efficient clinical trials is enrolling a sufficient number of 
patients to draw statistically meaningful conclusions.  The number of patients 
targeted for enrollment is specified in the protocol by statisticians and reaching this 
number is referred to as meeting the accrual goal. Trials that accrue few patients or 
take a long time to complete are considered non-performing and trials that close 
without meeting accrual goals are considered to have failed.  Opening trials that fail 
to meet accrual goals are costly, both financially and because they use scarce 
patient resources, with no scientific gain.[8]  
In 2010, the Institute of Medicine (IOM) reported that the clinical trials system 
was “approaching a state of crisis.”[6] The system was described as “bloated, 
cumbersome, inefficient, slow-paced, over managed, and expensive.”[9]  At the UNC 
Lineberger and across the nation, there are serious obstacles to efficiently 
developing new cancer treatments.  Difficulties with the national clinical trials system 
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in the United States are long-standing and have been difficult to address; concerns 
were first expressed shortly after the creation of NCI’s Cooperative Group Program 
more than 50 years ago.[10]  Three previous directors of the NCI each 
commissioned reviews of the system and their reports are described in the literature 
review. Innovative solutions are urgently needed to improve the clinical trials 
enterprise at the UNC Lineberger and nationally. 
Topic Selection and Research Question 
In order to decrease suffering and death from cancer, it is imperative that 
academic medical centers including the UNC Lineberger be able to conduct cancer 
clinical trials efficiently and effectively.  Investigators and leaders at the UNC 
Lineberger share national concerns about the length of time it takes to activate and 
complete trials; the current system is not working well.  A sense of urgency is 
present but no solutions or best practices have been identified for application at the 
UNC Lineberger.  A major national report states that the key to bringing about 
change in clinical trials efficiency will be based on “doing things differently rather 
than undertaking new activities.”[11]  There is consensus that things need to be 
done differently, but how?   
This study was designed in response to the need to investigate new options 
for improving cancer clinical trials efficiency.  To transform the call for novel solutions 
into a researchable topic, first the literature was reviewed to understand what 
recommendations and improvement initiatives pertaining to clinical trials had been 
undertaken thus far.  The fact that no cancer center in the United States was able to 
demonstrate positive results from implementation of the recommendations from 
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national reports issued over several decades underscored the need for a different 
approach.  To focus the inquiry at the local level, stakeholder analyses were 
conducted at the UNC Lineberger.  With a better understanding of the current 
situation and of the literature on clinical trials efficiency, organization development, 
and Appreciative Inquiry (AI), a hypothesis was generated that AI could be applied 
with the UNC Lineberger’s CPO and that doing so would directly and indirectly lead 
to improvements in clinical trials.  This case study was designed to investigate the 
question of how appreciative inquiry can be used to improve clinical trials efficiency 
and to deliver a case study report on a trial application of AI. 
Appreciative inquiry has been applied in health care organizations but has not 
previously been used as an approach to improving clinical trials efficiency.  This 
dissertation tests its application in a unique setting not accessible to outside 
investigators.  If AI is to be viewed as effective in healthcare, a broader evidence 
base is needed.  This case study seeks to contribute to that body of work and to 
improve the health of the public by identifying tools that can be used to build a more 
efficient cancer clinical trials system. 
   
 
Chapter 2: Review of the Literature 
To assess the current status of cancer clinical trials efficiency improvement 
initiatives nationally, a literature review was conducted using formal identification, 
selection, extraction, and synthesis methods.  Literature on organization 
development (OD) was reviewed to understand the evolution of the field and the 
emergence of AI.  An overview of case study research methods is also provided. 
I. Clinical Trials Efficiency 
Systematic Literature Review Methods 
To identify articles on clinical trials efficiency, primary keywords “clinical trials” 
were combined with efficiency, leadership, activation, administration, organizational 
design, and organizational change in a bibliographic database search using 
PubMed, CINAHL, and the Cochrane Library.  Because the topic could be covered 
by literature not included in these databases, Google Scholar was used to informally 
search for additional sources. The snowballing technique (perusing the reference 
lists of selected articles and books browsing books with adjacent call numbers) was 
used to identify relevant literature.  The Clinical Trials Toolkit from the Association of 
American Cancer Institutes (AACI) identified seminal reports on clinical trials 
efficiency.  A gray literature search was completed by contacting colleagues and 
known experts in the field.  The review was performed in March 2011. 
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Thirty-three articles on cancer clinical trials efficiency were included in the 
review, including four major reports, as well as presentations from recent AACI, 
ASCO, and AACR meetings.  The results of the search were uploaded into 
reference management software, EndNoteX4, to store citations, connect citations to 
electronic copies of articles, and to categorize the results. 
Clinical Trials Efficiency Literature Review Results 
Several articles described overarching problems with the clinical trials 
enterprise.  First among these was the undervaluation of clinical research.  For 
example, the president of the Association of Community Cancer Centers wrote: 
The historic undervaluation of clinical research is exemplified by the sizeable 
voluntary effort required by physicians to enroll patients, the philanthropic 
support that must supplement many clinical research programs, and the 
second-tier status allocated to clinical investigators by university leadership.  
Ironically, the turmoil affecting clinical research within the American 
healthcare system comes at a time when the potential to unmask some of the 
complexities of human tumor biology has never been greater.[12] 
An editorial responding to a 2010 report on clinical trials efficiency from the Institute 
of Medicine (IOM) summed it up in lay language: 
In other words: quit relying on investigators to design and conduct studies as 
a hobby, something that folks can only find time to do after dinner, when the 
kids are asleep. Novel concept. This might have something to do with the fact 
that as many as 40% of cancer clinical trials are never completed.[13] 
Another common problem has been described allegorically as silos, referring to lack 
of interactions across individuals and work groups that comprise clinical trials 
operations.  The problem of silos has been observed at all levels, locally at the UNC 
Lineberger and nationally between institutions, and the lingo is pervasive among 
clinical researchers.  Four major reports have been commissioned by directors of the 
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NCI over the last 15 years and provide insight into persistent problems with the 
clinical trials enterprise. 
A. National Reports on Cancer Clinical Trials Efficiency 
The NCI funds a large portion of the cancer clinical trials conducted in the US.  
For more than 50 years, the largest component of NCI’s clinical trials research has 
been the Clinical Trials Cooperative Group Program (Cooperative Group). The 
Cooperative Group has been instrumental in establishing the standards of cancer 
patient care and clinical research methods.  Advances include the increase in 
childhood cancer survival rates to nearly 80% from less than 10% in the 1950s; 
establishment of breast-conserving surgery as standard of care for localized breast 
cancer; improvements in cancer survival through the use of adjuvant treatment; and 
the identification of drugs that help prevent colon, breast, and prostate cancers in 
high risk patients.[6]  The Cooperative Group involves 3100 institutions and 14,000 
investigators who enroll 25,000 cancer patients each year.[6]  
Persistent and growing problems with the clinical trials enterprise in the US 
prompted four reports, some focused on the Cooperative Group Program but all 
applicable to improving the conduct of clinical trials at academic medical centers.  
These are: the NCI Clinical Trials Program Review Group report (1997), the Clinical 
Trials Working Group report (2005), the Operational Efficiency Working Group report 
(2010), and the Institute of Medicine Report on a National Cancer Clinical Trials 
System for the 21st Century (2010).  All emphasized the need to decrease time to 
trial activation.  The charges to the groups, key findings, and recommendations from 
the four reports are described here. 
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1. Report of the National Cancer Institute Clinical Trials Program Review Group  
(The Armitage Report).  
In 1996, the NCI director and the chair of the Extramural Board of Scientific 
Advisors commissioned an external review of the Cooperative Group Program in 
response to concerns that it was becoming increasingly inefficient and unresponsive 
to evolving needs.  The charge to this Clinical Trials Review Group was to 
recommend changes that would: 1) take advantage of the most promising 
opportunities in therapy and diagnosis; 2) prioritize the most important research 
questions so that they can be explored in the fastest possible time; 3) improve the 
organization, funding, review, and cooperation in the Cooperative Group Program; 
and 4) attract both patients and researchers to participate in clinical trials.[14]  
Recommendations in the Armitage Report (so named for the group’s chair) 
focused on organization, prioritization, participation, and funding.  These were grouped 
into several categories: data collection, standardization, and management; cooperation; 
process improvement; organizational and structural improvement; accrual; funding; and 
investigator recruitment.  The organizational and structural improvement 
recommendations were geared toward inter-institutional issues (e.g., within the Cancer 
Therapy Evaluation Program or the Community Clinical Oncology Program) rather than 
organization development at institutions conducting trials.[14]  An implementation 
committee report was completed in 1998.  This group concluded that the clinical trials 
system was hampered by the complexity that resulted from attempted collaborations 
that included multiple parties, such as investigators, physicians, industry, academia and 
NCI. The report said, "This complexity has bred inefficiencies and eroded the ability of 
the system to generate new ideas to reduce the cancer burden."[14] 
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2. Report of the Clinical Trials Working Group of the National Cancer Advisory 
Board: Restructuring the National Clinical Trials Enterprise (CTWG Report).  
In 2004, the Director of the NCI established the Clinical Trials Working Group 
(CTWG) to advise the National Cancer Advisory Board (NCAB) on the development, 
conduct, infrastructure, support, and coordination of cancer clinical trials across the 
NCI.[15]  The working group was asked to provide recommendations and a plan to 
improve coordination and research infrastructure for clinical trials research by 
removing institutional and regulatory barriers that inhibit collaboration.  The CTWG 
was asked to envision how clinical trials should be conducted in the era of 
bioinformatics and molecular medicine.  The group recognized that NCI-designated 
Cancer Centers were the primary source for clinical investigators and that federal 
funding for investigator-initiated trials (IITs) was critical.  In addition to the Armitage 
report, this group built on a 2003 report from NCI’s P30/P50 ad hoc working group: 
Advancing Translational Cancer Research: A Vision of the Cancer Center and SPORE 
Programs of the Future, so that cancer centers and translational science funding 
mechanisms (including P50, P01, and R01 grants) would be part of the framework.[15]  
The report was a detailed blueprint subtitled, Restructuring the National 
Cancer Clinical Trials Enterprise, that aimed to support clinical trials research in the 
21st century that would be driven by individualized oncologic medicine.[15]  The 
group reached consensus on four goals: 
1. Improve coordination and cooperation among the functionally diverse 
components of the current system, including industry and federal regulatory 
agencies; 
2. Improve prioritization and scientific quality by developing an open and 
transparent process for the design and prioritization of clinical trials that are 
science-driven and meet the needs of patient care; 
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3. Improve standardization of tools and procedures for trial design, data 
capture, data sharing, and administrative functions to minimize duplication of 
effort, and to facilitate development of a shared infrastructure to support an 
integrated national cancer clinical trials network; 
4. Improve operational efficiency by increasing the rate of patient accrual and 
reducing operational barriers so that trials can be initiated and executed in a 
timely, cost-effective manner. [15] 
The CTWG recommended 22 initiatives grouped into four themes: 
coordination, prioritization/scientific quality, standardization, and operational 
efficiency.  Coordination initiatives sought to enhance information sharing by 
providing incentives for collaborative team science and coordination of regulatory 
processes.  The prioritization/scientific quality initiatives suggested new processes 
for design and prioritization of clinical trials and for facilitating the conduct of 
correlative science and other ancillary studies.  Standardization initiatives supported 
development of tools and procedures to minimize duplication and reduce the effort 
required to initiate and conduct clinical trials.  Operational efficiency initiatives 
focused on improving patient accrual rates and reducing operational barriers to 
speed of both the initiation and conduct of clinical trials.  Options for restructuring the 
management and oversight of NCI’s clinical trials program were also included.   
Of particular relevance to the proposed research was Operational Efficiency 
New Initiative #2: “Identify the institutional barriers that prolong the time from concept 
approval to the accrual of the first patient, and develop solutions for overcoming these 
barriers.”  The CTWG reported that while specific barriers to rapid protocol activation 
had been documented at individual sites, no generalizable systems analysis had 
been conducted to clarify barriers and to identify solutions.  The CTWG suggested 
engaging academic management experts knowledgeable about evaluating workflows 
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to examine the clinical trial start-up process in real-world settings to understand the 
constrictions on trial initiation and develop recommendations for relieving bottlenecks.   
Also of note was Coordination New Initiative #2: “Realign NCI and academic 
incentives to promote collaborative team science.”  The CTWG found that NCI’s 
project selection and funding practices, as well as the deeply-ingrained promotion and 
recognition criteria of academic institutions, did not support collaborative research.  
The CTWG recommended realigning incentives by modifying NCI funding 
mechanisms, giving credit and adequate resources for participation in collaborative 
clinical trials and by modifying faculty performance evaluations at academic 
institutions, giving credit for participation in federally-funded clinical trials.  The goal 
was to create a culture in which investigators collaborate across disciplines, 
institutions, and programs to advance the design and conduct of cancer clinical trials. 
3. The Operational Efficiency Working Group of the Clinical Trials and Translational 
Research Advisory Committee: Compressing the Timeline for Cancer Clinical Trial 
Activation (OEWG Report)  
In December 2008, the Operational Efficiency Working Group (OEWG) was 
established.[11]  This group was asked to recommend strategies and design an 
implementation plan to reduce activation time for Cooperative Group trials, early drug 
development trials, and IITs at NCI-designated cancer centers, with a goal of 
reducing activation time by at least 50%.  The group was also charged with 
identifying strategies to increase the percentage of studies that reach their accrual 
targets in a timely fashion.  The work was divided into two phases and 
recommendations from the first phase on reducing trial activation time were issued in 
March 2010.  
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The OEWG excluded matters beyond NCI’s jurisdiction from its deliberations 
including: consent forms regulated by the Department of Health and Human 
Services; state laws and requirements; and congressional funding mandates.  The 
group reviewed available data on clinical trial timelines, identified the tasks required 
for trial activation, looked for barriers to timely activation, and discussed issues 
arising in the Cooperative Group and Cancer Center settings.  Separate target 
timelines were established for different categories of trials.  For IITs at Cancer 
Centers, a 90 day timeline was set for protocol review and revision, forms 
development, IRB review, and ancillary committee review.  All steps from protocol 
submission to trial activation, including institutional financial review and industry 
negotiations, were to be completed within 180 days. 
The OEWG developed 14 initiatives and implementation plans in two broad 
categories: management issues that directly addressed time to trial activation and 
important collateral issues.  Process improvements were recommended for IITs: 
1. Develop a center-specific action plan to achieve the OEWG target timeline 
for each step in IIT trial activation impacted by the cancer center 
2. Develop and implement new NCI and Cancer Center initiatives designed to 
streamline university contracting and financial review processes. Though 
reducing time on contracting and financial review is beyond the direct control 
of the cancer centers, it requires institution-wide changes that have the 
potential to benefit all types of trials. 
3. Develop a coordinated approach to standardization of protocol elements 
and protocol development tools in order to speed development and review of 
protocols 
4. Enhance funding and capabilities for use of biomarkers in clinical trials in 
order to speed activation of trials designed to incorporate integral and 
integrated biomarkers 
5. Perform a rigorous cancer center review of each proposed clinical trial 
concept in advance of protocol development in order to optimize use of 
clinical trial resources, speed trial development, and improve trial quality.[11] 
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The OEWG recommended that each cancer center develop its own action 
plan for achieving the target timeline because processes are impacted by structural 
factors such as the size of center, status as an independent or matrix cancer center 
(e.g., UNC Lineberger) within an academic medical center, and characteristics of its 
parent institution.  Processes are also influenced by the complexity of a cancer 
center’s clinical trials portfolio as well as center-specific factors such as decision-
making procedures, protocol development infrastructure, and leadership.  The report 
suggested that each center establish standards by which to judge success in 
meeting the target timelines and identify concrete steps for improvement such as: 
adding professional protocol writers and editors to staff; convening face-to-face 
meetings to resolve differences and minimize serial tweaking of protocols; convening 
regular clinical trials office staff meetings for timeline management and problem 
solving; and deploying project management software tools to track protocol 
development timelines. 
Recognizing the need for the NCI and the cancer centers to work together to 
improve time to activation, the OEWG recommended that the NCI provide 
supplemental funds to support implementation of action plans.  This resulted in the 
NCI’s Re-engineering of Protocol Implementation and Development (RaPID) grant 
program.  UNC applied for and received funds through this initiative, the details of 
which are provided below with local reports on efficiency at UNC.  Efforts continue 
locally and nationally to enact the recommendations of the OEWG report. 
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4. A National Cancer Clinical Trials System for the 21st Century:  
Reinvigorating the NCI Cooperative Group Program (IOM Report)  
At the request of the NCI director, the Institute of Medicine (IOM) conducted a 
study of cancer clinical trials and the Cooperative Group Program to develop 
recommendations on how to improve the system.  The IOM’s review built on work 
that had resulted from the CTWG and the OEWG recommendations.  In its 2010 
report, the IOM encapsulated its findings with the following statement: 
In sum, the academic, government, and commercial sectors must join with the 
public to develop a 21st-century multidisciplinary clinical trials system to more 
effectively leverage scientific advancements and translate them into public 
health benefits by improving the science; technology; efficiency; and timely 
creation, launch, and completion of the highest-priority cancer clinical trials.  
With adequate funds and support, a more effective and efficient clinical trial 
system will speed the pace of advances in cancer patient care.[6] 
The IOM found that the NCI’s Cooperative Group Program had become 
stagnant, inefficient, cumbersome, underfunded, overly complex and managerially 
redundant.  The average time required to design, approve, and activate trials was 
two years and many – about 40% -- trials were not completed at all. Inefficiencies 
led to lengthy delays at each step of trial development, during which time trials lost 
scientific relevancy and communication between stakeholders became ineffective.  
The IOM focused their recommendations on four broad goals: 
1. Consolidation and Efficiency. Improve the efficiency and reduce the 
average time for the design and launch of innovative clinical trials by 
consolidating functions, committees, and Cooperative Groups; streamlining 
oversight processes; facilitating collaboration; and streamlining and 
standardizing data collection and analysis 
2. Science.  Incorporate innovation in science and trial design, for example, in 
studies identifying biomarkers that can predict therapeutic response.  
3. Funding and Support. Adequately support those clinical trials that have the 
greatest possibility of improving survival and the quality of life for cancer 
patients, and increase the rate of clinical trial completion and publication. 
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4. Participation.  Incentivize the participation of patients and physician in 
clinical trials by providing adequate funds to cover the costs of research and 
by reimbursing the costs of standard patient care during the trial.[6] 
The IOM reiterated that publicly-funded clinical trials, vital to advancing 
science and patient care, are growing in importance as industry trials are conducted 
outside the United States with increasing frequency.  The report also urged 
researchers to publish negative results, an important step in setting standards of 
cancer patient care.  The committee’s vision for an ideal cancer clinical trials system 
included support for clinical investigators; the IOM found that the current system 
does not adequately recognize, reward, or support collaborative work.  The IOM 
underscored the ideas that translating discoveries into benefits for patients requires 
a robust clinical trials system and that clinical researchers need training, mentoring, 
and paid time set-aside to master this challenging endeavor.  As did its predecessor 
committees, the IOM recommended that academic medical centers develop policies 
and evaluation metrics for promotion and tenure decisions that recognize and 
reward clinical and team research.  This group noted that effective R&D 
organizations don’t just do research, they allocate resources to improving how they 
do research.  The IOM report posited that expertise from a range of disciplines 
including social science, management, and marketing would be necessary to 
develop novel approaches to solving the intractable clinical trials efficiency 
problems.  The authors believe that at the heart of the issue is a clinical trials 
infrastructure that has not evolved to accommodate the rapid pace of biomedical 
discovery and that many of the challenges derive from systems problems rather than 
scientific ones. 
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B. Literature on Cancer Clinical Trials Process Analyses 
In addition to national reports, there is a body of literature describing work to 
better understand cancer clinical trials processes and analyze barriers to completion.  
These efforts have been spearheaded by David Dilts, a management scientist, and 
Alan Sandler, an oncologist.  They developed what is now known as the Dilts and 
Sandler method with two parts: 1) process steps are identified and mapped; and 2) 
timing analyses are conducted.[16]  A process map is created as one large complete 
diagram, graphically portraying all the processes required to activate a trial.  The 
Dilts and Sandler method examines three types of barriers: procedural, structural, 
and infrastructural.  Procedural barriers arise from processes or steps which are 
required to activate a study but may inhibit problem-solving actions.  Structural 
barriers result when different participants in the process follow a different ordering of 
steps, which can lead to miscommunication and misunderstandings.  Infrastructural 
barriers relate to the design of the underlying system and its support of 
interconnections.[16]  For Cooperative Group studies, there is a fourth type of 
barrier, synchronicity, the need to compile various components before a trial can 
proceed to other parts of the process.[17] 
Dilts and Sandler have analyzed barriers and published more than six papers 
with staggering results.  In a study using four cancer centers (including the UNC 
Lineberger), two Cooperative Groups, and the NCI Cancer Therapy Evaluation 
Program (CTEP), they found that opening a phase III Cooperative Group therapeutic 
trial required 769 steps, 36 approvals, and a median range of 2.5 years from concept 
review to opening.[18]  They used the children’s game, Chutes and Ladders, to 
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describe the process because while it is possible to bypass steps (ladders), trials 
may be returned to an earlier point in the process (chutes).  Dilts and Sandler also 
found that a large number of redundant or overlapping steps added no value to the 
process.  Eliminating these would be one way to decrease elapsed time.[17] 
Dilts and colleagues confirmed their hypothesis that the amount of time 
elapsed between the letter of intent or concept initiation and the activation of a trial is 
inversely related to the likelihood the trial will reach its accrual goal.[19] To decrease 
delays due to process barriers, Dilts and Sandler call for researching on streamlining 
internal and external groups and processes, stressing that even simple changes 
may lead to extensive looping that substantially slows time to activation.[17]   
Kurzrock and colleagues described the outcomes of Project Zero Delay, 
undertaken in partnership between MD Anderson Cancer Center and AstraZeneca 
Pharmaceuticals.  The objective was to enroll a patient without significant delay after 
FDA approval of the trial’s investigational new drug application by focusing on: 
communication; identifying and matching key timelines; alignment of priorities; and 
tackling administrative processes in parallel.[20]  The team determined the most 
common obstacles to trial activation were: frequent and complex amendments to 
protocols; contract and budget negotiations; IRB communication delays; and a 
complicated web of approval processes with interdependent steps.  An important 
finding was that significant efficiency could be gained, without compromising patient 
safety or research quality, by allowing processes to occur in parallel rather than 
sequentially.[20]  The team found the following were necessary to ensure rapid 
activation of trials conducted through industry-academia partnerships:  
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• Frequent interactions and sharing of information by people at all levels 
• A highly motivated protocol champion (the PI) with authority over a well-
qualified team of personnel; 
• Support from upper levels of administration. 
• Experienced management teams coordinating from start to finish;  
• Mutual understanding of motivations and willingness to examine timelines.  
• A master agreement to streamline contracting and budgeting  
• A shared goal of bringing novel cancer drugs to patients faster while 
maintaining safety and quality.[20] 
Adjei, Yasko, and colleagues at Roswell Park Cancer Institute described their 
strategies to increase the number of high-impact intervention studies, increase 
accrual, and improve activation speed.[21]  They hypothesized that having a large 
number of trials open to accrual at the same time, especially asking similar questions 
or targeting the same patients, was a significant obstacle to efficiency.  In order to 
streamline the protocol development process while maintaining a portfolio of high-
impact trials, a committee was established to review and approve study concepts 
before the protocol could proceed to scientific review.  An accrual-to-study ratio 
metric, defined as the total annual accrual divided by the number of active studies, 
was established at > 5 and used as a review criterion.  After three years, the team 
found: the number of submitted concepts decreased by 50%; the accrual to trials 
increased by 45%; and the time from concept submission to study activation was 
reduced by 25 days to a median of 107 days.  In addition, their study portfolio had 
improved and included more IITs, phase I studies, and collaborative studies.   
Another mandate of national reports was to share best practices and lessons 
learned.  Yasko et al. provided several from their experience, noting that clinical 
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research culture change takes time and the need for change agents to remain 
patient and positive in the early phases.  Recommendations included:  
• establish written goals and a set of metrics to measure the goals, distribute 
the metrics widely, and frequently measure the goals using the established 
metrics; be consistent in review of all studies for all investigators;  
• ensure a well-functioning partnership between clinical research leadership 
and committee leaders and members, with frequent counsel from 
leadership to committee leaders and members about handling appeals 
from investigators whose protocols are denied;  
• be aware that the importance of disease-specific research groups will 
increase since they will determine which studies to close or focus accrual 
efforts to meet the study ratio;  
• know the accrual target and accrual to date of industry-sponsored or 
Cooperative Group studies when evaluating for approval to avoid opening 
cost-ineffective studies of these types.  
Yasko also joined with two facility leaders from the UNC Lineberger’s CPO 
and others in 2010 to co-author, Clinical Research Site Infrastructure and Efficiency, 
a synthesis of ASCO abstracts included in a series of articles on attributes of 
exemplary research sites.[22]  This article summarized information including:  
• Work by Dilts, Adjei, et al. showing that in 2.5 years of trial development 
time, enthusiasm dropped and scientific relevance decreased due to 
standard-of-case changes.  This trial had an accrual goal of 1,200 patients 
but only enrolled 23 patients and closed early; 
• Work by Cheng et al. demonstrating that trials that do not enroll a patient 
within two months of activation are significantly less likely to meet accrual 
goals no matter how long they stay open;  
• Work by Durivage et al. on the need for trial selection strategies and 
closure rules for non-performing studies to conserve resources.  In their 
study of 14 NCI-designated cancer centers, $81,000 was spent on 
average per center per year on trials that accrued no patients;  
• Analysis by Durivage et al. on 170 phase II trials at 9 cancer centers 
showing that 47% closed before completion and 21% of enrolled patients 
were on a trial that closed due to poor accrual.  Slow accruing trials 
remained open for a median of 28 months, using substantial resources.[22] 
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C. Clinical Trials Efficiency Assessments and Initiatives at the UNC Lineberger 
On several occasions in the last decade, the UNC Lineberger has sought 
advice from external cancer research advisors regarding its clinical trials operations.  
Reports from three key consultations are briefly summarized here.  In 2002, the 
Scientific Advisory Board concluded the center’s large number of non-performing 
trials was a significant problem.  The board recommended: 1). filtering out protocols 
that are highly unlikely to accrue or that address trivial scientific questions at an early 
stage of development and reviewing concepts at the highest level of the center, not 
the CPO; 2) analyzing past non-performing protocols and preventing protocols with 
similar characteristics (e.g., target patients, physicians) from moving forward; 3) 
establishing a policy to address competing protocols; and 4) predefining time points 
by which trials will be closed and rigidly enforcing the standards.[23] 
In 2004 the advisors returned to find that despite the increased number of 
creative protocols addressing cutting edge questions, many were not meeting 
accrual goals.  The advisors noted that with more investigators conducting trials, 
there was increased stress on a system that was overburdened by studies that 
would never reach accrual goals.  Advisors found the system to be “inefficient and 
likely overly expensive.”  They recommended: establishing and enforcing better 
prioritization methods to limit active trials to a manageable number; recruiting full-
time clinicians to expand the clinical base, staff the new hospital, and accrue to 
clinical trials; and increasing the number of dedicated research nurses with dual 
reporting to the CPO and to the disease team leader. 
In 2010, the UNC Lineberger received funding from the NCI’s RaPID initiative 
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(described above) to implement recommendations of the OEWG report.  UNC’s 
RaPID grant hypothesized that efficiency and speed of activation depended on: 1) 
appropriate prioritization of work including rigorous review at the outset and ability to 
fast track high priority trials; 2) dedicated personnel to aid in development of 
protocols and Letters of Intent, to track progress of each protocol, and to identify 
barriers; 3) metrics for monitoring processes and work flow, managing portfolios, and 
modifying the activation processes based on identified barriers.  Major areas of 
focus included: 1) self-study of barriers and examples of fast activation that used 
checklists and tracking methods; 2) development of additional checklists and a 
dashboard to track milestones; 3) hiring an activation specialist to monitor progress; 
and 4) development of automated reports to help with prioritization.[24]   
In March 2011, Dr. Alex Adjei, Senior Vice President of Clinical Research and 
Chair of the Department of Medicine at Roswell Park Cancer Institute (whose work is 
referenced in section B above), completed a review of UNC Lineberger’s clinical trial 
operations.  Dr. Adjei reported a concerning disconnect between the CPO 
management and the clinician investigators.  Most striking was that the report of 
protocol development timelines he received from the CPO management differed 
significantly from reports he received from investigators (6 and 12 months, 
respectively).  He recommended that a physician be given the resources, budgetary 
authority, and reporting relationships necessary to manage the clinical trials 
enterprise and undertake a reorganization of the clinical trials office in consultation 
with UNC Lineberger leadership.  Dr. Adjei recommended that clinical investigators 
be asked about their impressions and suggestions for improvement. 
   
23 
Discussion and Conclusions 
The literature makes it is clear that having an effective and efficient clinical 
trials program is essential to making progress against cancer, a leading cause of 
death in the United States.  Patient lives are lost when the development of new 
treatments is delayed.  Clinical trials efficiency issues have been analyzed, 
implementation plans have been devised, and some institutions have made some 
small improvements in targeted areas.  There is hope amongst the cancer research 
community that the OEWG’s timelines by which specific steps must be reached and 
the IOM’s proposal to consolidate functions within the Cooperative Group system will 
lead to improvements.  It has been stated that there is no singular fault in the clinical 
trials system; rather it is a complex process with weak links between key 
components.  The lack of timely trial activation trials has been criticized since the 
beginning-- the NCI’s Cooperative Group Program was first chastised for inefficiency 
in 1959, only three years after its creation.[10] However, the problems had not been 
systematically analyzed until recent decades.   
The changes and recommendations from the four reports are summarized in 
the table on the following page.  The persistence of issues despite the identification of 
potential solutions suggests a new approach is needed.  Perhaps the key to improving 
cancer clinical trials is a better understanding of the people, their motivations, and 
behaviors, rather than a better understanding of the processes in the system.  A 
clinical trials blog encapsulated the sentiment heard nation-wide and at the UNC 
Lineberger: “The US cancer clinical trials system is broken.  Fix it.”[13]   
   
 
Table 1: Summary of National Reports 
 Armitage Report CTWG Report OEWG Report IOM Report 
Charge Recommend changes 
to 1) take advantage 
of the promising 
opportunities in 
therapy and 
diagnosis;  
2) prioritize most 
important research 
questions;3) improve 
organization, funding, 
review, & cooperation; 
and 4) attract patients 
and researchers to 
clinical trials 
participation 
1) Develop 
recommendations & 
implementation plan to 
improve coordination & 
research infrastructure 
by removing institutional 
and regulatory barriers 
that inhibit 
collaboration.  2) 
Envision conduct of 
clinical trials in era of 
bioinformatics and 
molecular medicine. 
Recommend 
strategies & 
implementation plan 
to reduce time to 
activation by >50% 
and to increase 
percentage of 
studies that reach 
accrual goals 
1) Conduct a 
consensus study of 
cancer clinical trials 
and the Clinical Trials 
Cooperative Group 
Program and 2) 
Develop 
recommendations to 
improve the current 
system 
Focus Organization, 
prioritization, 
participation, and 
funding 
Coordination, 
collaboration, adoption 
of new technologies 
Institutional barriers 
to activation 
Efficient and effective 
translation of research 
discoveries into timely 
clinical applications 
Recommendation 
groupings 
Data collection, 
standardization, & 
management; 
cooperation; process, 
organization and 
structural 
improvement; accrual; 
funding; investigator 
recruitment 
Coordination, 
prioritization/scientific 
quality, standardization, 
operational efficiency 
Management issues 
directly addressing 
time to activation and 
collateral issues of 
importance to clinical 
trials system. 
Consolidation & 
efficiency; science; 
funding & support; 
participation 
Key points 
relevant to this 
proposal 
Clinical trials system 
is hampered by the 
complexity of 
attempted 
collaborations 
Engage management 
experts to understand 
processes in real-world 
settings.  
 
Culture/practices of 
academia don’t support 
collaboration.  
Key to change lies in 
doing things 
differently rather than 
doing different things 
Effective organizations 
don’t just do research, 
they improve how they 
do research.  Systems 
issues not scientific 
ones are impeding 
progress 
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Many talented individuals have sought to improve the cancer clinical trials system.  
Additional barriers to achieving the desired goals must be present -- can the 
improvements not be successfully implemented or do the suggestions not work when 
implemented?   
From the review of literature on clinical trials efficiency, several clues about 
possible next steps were gleaned.  The OEWG report said the key to change would 
lie in doing things differently rather than doing different things.  Adjei et al. said that 
clinical research culture change takes time and that change agents would need to 
remain patient and positive.  Kurzock et al. found that frequent interactions and 
sharing of information by people at all levels, a mutual understanding of incentives, 
and a willingness to openly examine processes in context of those drivers were key 
to reducing delays.  Dilts et al. found that miscommunication and misunderstanding 
were significant problems and that the impact of lack of resources paled in 
comparison to that of lack of coordination.  Dilts also said that it will take more than 
recommendations and hope to solve the problems with clinical cancer research.  
The IOM suggested that novel approaches involving disciplines such as social 
science, management, and marketing be used.   
All of these statements suggest that organization development could be used 
to improve the cancer clinical trials enterprise, bringing strategies from multiple 
social sciences to bear on the challenges.  Organization development could provide 
an alternative or supplement to the ideas generated previously.  The relevant 
literature is described below and no applications to clinical trials organizations were 
found, making the proposed research a potentially novel application.
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II. Organization Development*  
Organization Development (OD) is a field of applied behavioral science that 
focuses on understanding and managing change in organizations.  OD draws on 
theories and approaches from a wide range of disciplines including anthropology, 
economics, political science, psychology, and sociology to make organizations more 
effective.  OD involves implementing change and developing the organization itself, 
to the benefit of both the institution and the individuals who comprise it.  French and 
Bell articulated this duality of purpose:  
The idea is this: it is possible for the people within an organization 
collaboratively to manage the culture of that organization in such a way that 
the goals and purposes of the organization are attained at the same time that 
human values of individuals within the organization are furthered.[25]  
Over the last fifty years, there have been many definitions of OD with debate 
over its defining characteristics.  This discussion has expanded in recent years in 
response to new patterns of practice.  What many consider the first formal definition  
of OD was put forth in 1969 by Richard Beckhard describing an effort that is 
“planned, organization-wide, and managed from the top, to increase organization 
effectiveness and health through planned interventions in the organization’s 
processes, using behavioral-science knowledge.” [26]  Another early leader in the 
field, Warren Bennis, defined OD as “a response to change, a complex educational 
strategy intended to change beliefs, attitudes, values, and structures of organizations 
so that they can better adapt to new technologies, markets, and challenges, and the 
                                            
* The field was inaugurated as and continues to be referred to by many scholars as “Organization 
Development,” parallel to “human development.”  Though “Organizational Development” has 
increased in use, this dissertation uses the conventional term. 
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dizzying rate of change itself.”[26]  More recently, Thomas Cummings sought to 
integrate emerging aspects of OD as “a system-wide process of applying behavioral-
science knowledge to the planned change and development of the strategies, design 
components, and processes that enable organizations to be effective.”[27]   
Kurt Lewin, a social psychologist considered the father of OD, believed that 
science and actions should be iterative.  Lewin sought to join science with practical 
applications and became famous for the maxim, “no action without research and no 
research without action.”[28]  In creating action-research, Lewin advanced the 
concept that diagnosing problems in organizations was not enough to lead change 
and research could be of value to practitioners.  In his 1946 article, Action Research 
and Minority Problems, Lewin describes a situation familiar to the UNC Lineberger: 
“Two basic facts emerged from these contacts: there exists a great amount of 
good-will, of readiness to face the problem squarely and really to do something 
about it.  If this amount of serious good-will could be transformed into organized, 
efficient action, there would be no danger for intergroup relations in the United 
States. But exactly here lies the difficulty.  These eager people feel to be in a 
fog.  They feel in the fog on three counts: 1) what is the present situation? 2) 
what are the dangers? 3) and most important of all, what shall we do?”[29] 
Lewin had been asked, in the wake of the holocaust, to assist communities in 
understanding and eliminating prejudices through new methods of social inquiry.[30]  
This work to improve intergroup relations became known as sensitivity training and 
led to the establishment of the National Training Laboratories, where training groups 
learned about group dynamics, leadership, interpersonal relations, and personal 
growth.[30]  Once these methods were applied to industry, the field of “organization 
development” took root.[30]   
 OD is built on core psychological concepts about the nature of humans in 
organizations, the motivations underlying behavior, resistance to change, and 
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focusing on groups to enact organizational change and is influenced by humanistic 
psychology, which prompts examination of subjective experiences, values, intentions 
and perceptions that influence choices.[27]  The field places a high value on human 
potential, asserting that humans have tremendous capacity for self-determination, 
creativity, and psychological growth.[27]  At the same time, OD recognizes that 
organizations are often structured in ways that inhibit this precious human 
potential.[27]  For example, “command and control” management presumes that 
some members of the organization are inferior to others.  In organizations of this 
type, connections between individuals are expected to be rational and exist to further 
organizational goals, when the relationships themselves are not valued.  OD seeks 
to create work environments that promote maturity and interpersonal competence 
and values relationships.[27]   
Since its inception, OD has been used in many different types of industries 
and organizations, with a body of literature published by practitioners and 
academicians.  Marvin Weisbord’s 1976 article, “Why Organization Development 
Hasn’t Worked (so far) in Medical Centers” is particularly relevant.  Weisbord found it 
difficult to used OD with academic medical centers for three reasons:  
1. Medical centers have few of the formal characteristics of industrial firms, 
where OD, like all management science, was first recognized, tested, and 
developed. 
2. Physicians and scientists are socialized to a form of rational, autonomous, 
specialized, expert behavior, which is antithetical to the organization of 
any but the more narrow individualized pursuits. 
3. Medical centers, therefore, require three different social systems, not one, 
as in industry.  The links among the task system which administrators 
manage, the identity systems which undergirds professional status, and the 
governance systems, which sets standards, are extremely tenuous.[31] 
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Weisbord found that organizations functioned well when four structural 
elements were balanced, contributing to the synergy of the organization: task 
interdependence, concrete goals, performance measures, and formal authority.[31]  
He observed that academic medical centers tended to have abstract goals, diffuse 
authority, low interdependence, and few performance measures.[31]  Weisbord 
found that high synergy institutions can use OD to develop procedures that increase 
productivity and self-esteem.[31]  Weisbord recommended increasing the synergy of 
academic medical organizations by working to clarify goals and better align key 
elements.  He also suggested that the field add “structure-creating interventions” to 
OD’s repertoire, meaning approaches that enhance and improve relationships within 
an organization rather than stifle them (e.g., generative forms of OD).[31]   
Soon after, Kenneth Gergen published his article, “Toward Generative 
Theory,” which would have a significant impact on the evolution of the OD field and 
emerging forms of practice.[28]  In Gergen’s view social psychology theory failed to 
“challenge prevailing assumptions regarding the nature of social life and to offer 
fresh alternatives to contemporary theory.”[32]  He thought that social psychology 
theory, which served at the time as the underpinnings of OD, needed to move away 
from establishing and verifying facts upon which to intervene.  At the same time, OD 
practitioners began reporting that the pace of change in organizations made it 
difficult to obtain accurate data on which to base objective assessments and that 
they were finding that problem-centric approaches prompted increased resistance to 
change.[28]  As generative forms of OD became more common, the field underwent 
what some scholars consider a bifurcation.  Bushe and Marshak detailed similarities 
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and differences between two branches of OD practice that they characterize as 
diagnostic (or classic) OD and dialogic OD.[28]  A key difference is that dialogic OD 
works to change the frameworks that influence behavior rather than attempting to 
directly change behavior.[28]  AI is one of several forms of dialogic OD.  Its 
development, principles, methodology and prior applications will be described below.   
Discussion and Conclusions 
With the evolution of the OD field toward generative theories, current options 
such as AI seem better suited than classic OD for use in academic medicine.  
Gergen noted that when the pace of change in organizations is high (as is the case 
at the UNC Lineberger), diagnostic forms of OD are difficult to use and dialogic 
forms may be a better choice.  Dialogic forms of OD have been used successfully 
with nurses and at medical schools (described in the next section), suggesting that 
applying a dialogic form of OD could at the UNC Lineberger could be beneficial to 
the organization.  The distinctive multidisciplinary nature of cancer care and 
research at UNC, which gives it high levels of synergy, may make the organization 
amenable to a generative form of OD.  A systematic review of AI literature was 
performed to further examine the potential appropriateness of using AI in this case.   
III. Appreciative Inquiry 
Systematic Literature Review Methods 
Key words “appreciative inquiry” were combined with healthcare, medicine, 
medical centers, physicians, and cancer using PubMed.  Because relevant literature 
about AI could be housed in other databases, Google Scholar was used.  The 
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snowballing technique was used to identify relevant literature from reference lists.  A 
gray literature search was also completed by contacting colleagues and known 
experts in the field and produced numerous sources, including extensive training 
materials for AI practitioners. The search was conducted in April 2011.   
Fourteen articles and books on AI were included in the review.  The PubMed 
keyword search revealed that AI has been applied in a wide range of healthcare 
settings including nursing, primary care, HIV care, acute care, and pain 
management and applied in support of nurse retention, to prevent burn-out among 
physicians, to investigate how faculty in academic medicine experience 
collaboration, and to improve nurse-physician communication.  One article related to 
cancer services was identified but none were found about cancer research or cancer 
clinical trials.  Several books were included in the review including Cooperrider’s 
Appreciative Inquiry Handbook, Hammond’s The Thin Book of Appreciative Inquiry, 
and Stavros and Hinrich’s The Thin Book of SOAR.  The results of the search were 
uploaded into reference management software, EndNoteX4, to store citations, 
connect citations to electronic copies of articles, and to categorize the results. 
Through completion of an online AI workshop in May 2011, additional materials 
were obtained including six articles, 15 recorded lectures, five interview guides, 
summit materials, and a link to the AI commons (http://appreciativeinquiry.case.edu) 
where 16 classic articles, 22 case studies, and links to other positive change websites 
are available.  Titles of dissertations that have used AI are also posted in the AI 
commons.  There is an AI journal, AI Practitioner, and its website provides an index by 
subject.  One issue (May 2004) was dedicated to positive change in health care.  
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AI Literature Review Results  
David Cooperrider first articulated his ideas about the theory and practice of AI 
in 1986 in his doctoral dissertation at Case Western Reserve University.  Cooperrider 
and his advisor, Suresh Srivastva, introduced AI to the OD field with their article, 
“Appreciative Inquiry into Organizational Life,” that called for a shift from deficit-based 
theory of change to “a positive, life-centric theory.”[33] In a recent publication, 
Cooperrider and Whitney recounted the many ways AI has been characterized, 
summing it up as “a philosophy of knowing, a normative stance, a methodology for 
managing change, and as an approach to leadership and human development.”[34] 
This strengths-based, collaborative approach to change revolves around the 
idea that in every organization, something works well. [35]  Cooperrider established 
four foundations for the practice of AI:  
1. Inquiry into “the art of the possible” in organizational life should begin with 
appreciation. 
2. Inquiry into what is possible should yield information that is applicable. 
3. Inquiry into what is possible should be provocative. 
4. Inquiry into the human potential of organizational life should be 
collaborative.[36] 
Cooperrider speculated that human systems grow in the direction of what they study, 
so that asking questions about what is good and what is possible would be more 
likely to lead to positive change than studying an organization’s problems.[37]  That 
is to say that when organizations study problems and conflicts, they find that their 
problems grow and conflicts increase but organizations that study ideals and 
achievements find these aspects flourish.[36]  The Pygmalion effect (aka self-
fulfilling prophecy) is often used to explain this: a phenomenon where the greater the 
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expectation placed on people (notably students and employees), the better they 
perform.  From this, five central principles for the application of AI were developed: 
1. The Constructionist Principle: Social knowledge and organizational destiny 
are interwoven. 
2. The Principle of Simultaneity: Inquiry and change can and should happen 
simultaneously. 
3. The Poetic Principle: Any topic related to the human experience in 
systems or organization can be studied and the choice of inquiry affects 
the focus of change. 
4. The Anticipatory Principle: Collective imagination and discourse about the 
future is the most important resource for constructive organizational change. 
5. The Positive Principle: Change requires positive affect and social bonding.  
The more positive the questions, the more effective the change.[36] 
The two fundamental points about AI are that organizations move in the 
direction of what they study and that AI makes a conscious choice to study the best 
of an organization, its “positive core.”[36]  To concisely describe the steps used to 
build on this positive core, the action research phases of AI are called the 4-D Cycle 
of Discovery, Dream, Design, and Destiny.[38]  This cycle has also been described 
as five generic processes: 1) Choose the positive as the focus of inquiry; 2) Inquire 
into exceptionally positive 
moments; 3) Share the stories 
and identify life-giving forces;  
4) Create shared images of a 
positive future; and 5) Innovate 
and improvise ways to create that 
future.[39]   Cooperrider & Whitney 2007[1] 
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The first step in AI is selection of the affirmative topic, which represents what 
people in the organization genuinely want to learn more about. Most inquiries adapt 
or expand on four foundational questions about the selected topic:   
1. What was a peak experience or high point? 
2. What are the things valued most about yourself, the nature of your work, 
your organization? 
3. What are the core factors that “give life” to organizing? 
4. What are three wishes to heighten vitality and health?[36] 
The AI process has been applied effectively in many industries, including 
healthcare.  Noteably, AI has been applied to bring about culture change in medical 
schools and to improve communication between nurses and other healthcare 
providers.  At the Indiana University School of Medicine, interest in generating 
culture change sparked its “Relational-Centered Care Initiative.”[40]  The Steering 
Team’s goal was to foster a more caring, respectful, and collaborative culture 
throughout their medical school.  The team used a theoretical framework of Complex 
Responsive Processes of Relating, which describes how large-scale patterns of 
interactions can be changed by changing local, small-scale behaviors.[40]  Through 
the AI process, attention was brought to exemplary professional behavior which led 
to more mindful and intentional behavior within the organization.  The team found 
that the impact of the AI initiative was observable in numerous ways including the 
conduct of daily work and meetings, through increased participation in the initiative, 
and by sharp measurement increases in student satisfaction.  This case study 
demonstrated that AI can be used to generate culture change in a medical school at 
a public university (like UNC).[40] 
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AI initiatives with nurses have demonstrated that it can be applied effectively 
with health care organizations, where moving away from a diagnostic approach to 
change is particularly challenging.  Havens, Wood, and Leeman partnered with 
nursing leaders at six community hospitals to improve work environments for nurses.  
The project sought to improve communication and collaboration among nurses and 
other health care professionals; enhance nurse involvement in organizational and 
clinical decision making; and to enhance cultural awareness and sensitivity.[41]  The 
team found significant challenges to initiating an AI process in a healthcare 
organization because the AI approach was perceived by participants as very foreign.  
However, AI provided several advantages over traditional quality improvement 
techniques for addressing communication, collaboration, decision-making, and 
cultural sensitivity issues.[41]  Effects of the AI process were observable in individual 
interactions and in meetings.  This case study demonstrated that, with time and 
patience, paradigm shifts in healthcare organizations can be made using AI and that 
a positive approach to change can spread across an institution.   
Wood also published case studies about using AI with nurses to improve the 
organizations and professional practices at Lovelace Health Systems and at the 
Children’s Hospital of Philadelphia.[42]  At Lovelace, the topic focused on nurse 
retention (why nurses choose to stay employed there) and at the Children’s Hospital 
of Philadelphia the focus was creating a positive future for the Department of 
Nursing.  After the initiative at Lovelace, nurse turnover was reduced by 13%, the 
vacancy rate was reduced 30%, its rating as a place for nurses to work increased 
16% and patient satisfaction rose 20%.[42]  Both cases demonstrated that AI could 
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be used effectively to improve environments for nurses and their patients.   
In the United Kingdom, one of the first applications of AI in healthcare was to 
evaluate a change process related to cancer services.  The Cancer Services 
Collaborative (CSC) is a National Health Services Programme focused on improving 
patient experiences that was established to address the fact that cancer outcomes in 
England varied by geography and social class.[43]  Previous evaluations of the CSC 
had found the program had met many of its goals and the goal of this evaluation was 
to discover the ways in which the services had been successful and what worked in 
changing services.  AI was selected as the evaluation tool to study the process of 
change because its leaders wanted an evaluation approach that would support the 
CSC’s work to encourage innovation among staff.[43]  The use of AI to evaluate the 
cancer service changes was considered successful.  In addition, using AI had a 
positive impact on the staff conducting the evaluation and on the stakeholders who 
were interviewed because the AI process helped discover the organization’s shared 
commitment to improving the lives of people with cancer.[43] 
A meta-analysis of AI case studies found that AI is more likely to be 
transformational when the focus is on changing how people think rather than what 
they do.[44]  Bushe and Kassam learned that AI is less likely to be transformational 
when it used to try to change existing practices than when new practices are 
improvised.[44]  Barrett and Fry wrote that AI is “not about implementing a change to 
get somewhere; it is about changing…convening, conversing, and relating with each 
other in order to tap into the natural capacity for cooperation and change that is in 
every system.”[45]   
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Discussion and Conclusions 
The literature on AI provides a thorough introduction to its philosophy and 
application.  Detailed educational materials are available on how to construct and 
carry out an AI initiative.  AI has been used successfully with nurses and at medical 
schools, supporting the idea that it could be effectively used with the UNC 
Lineberger’s clinical trials personnel.  The literature provides caution that using AI in 
academic medicine poses particular challenges due the diagnostic culture of the 
profession, but the distinctive multidisciplinary nature of cancer care and research at 
UNC may make the organization reasonably receptive to this form of OD.   
Because AI builds on what works, it brings the potential to generate change 
with minimal risk of negative impact on the organization.  This makes it a good 
choice for study at the UNC Lineberger where there are reservations about the 
potential negative effects of change efforts.  Diagnosing conditions and seeking cure 
is the basis of medical practice, but organizations cannot be cured of themselves, so 
a dialogic form of OD is a better choice than diagnostic (or classic) OD in this case.  
Problem-based approaches generally fail to address systemic issues and can further 
erode trust, but appreciation enables people to see beyond obstacles and 
limitations.  Even when AI is not transformational (and sometimes it is), experiences 
described in the literature suggest it can generate significant positive change.   
The lack of effective national recommendations had left stakeholders at the 
UNC Lineberger to simply hope that their efficiency will improve.  The AI literature 
says that dwelling on problems is an inherently conservative approach and AI 
practitioners often quote Einstein: “The significant problems we face cannot be 
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solved at the same level of thinking we were at when we created them”. [39] 
Operating from a problem solving mentality risks affirming the status quo and the 
status quo is not acceptable if we are to save more lives from cancer.  AI may 
provide an alternative approach to creating change in the efficiency of cancer clinical 
trials.  A descriptive case study could provide useful information about whether and 
how it could be used.  To best formulate the framework for this research, the 
literature on case study research design and methods literature was reviewed. 
IV. Case Study Research 
 The case study is a research strategy often used to address descriptive or 
explanatory questions in the social sciences.[46]  In the 4th edition of his book on 
case study research design and methods, Yin provides this definition:  
A case study is an empirical inquiry that investigates a contemporary 
phenomenon in depth and within its real-life context, especially when the 
boundaries between phenomenon and context are not clearly evident.[47] 
Qualitative, quantitative, or both types of data can be used in case studies, generally 
obtained from one or more of six sources: documentation, archival records, 
interviews, direct observation, participant-observation, and physical artifacts.[47] 
Case study research design can comprise single or multiple cases with single or 
multiple units of analysis (holistic vs. embedded designs).[47]  A multiple case study 
may be preferred when sufficient resources and opportunities are available; 
however, a single case study may be justified when it represents a critical case 
testing a well-formulated theory, embodies an extreme or unique case, is 
representative or typical, is a revelatory case; or is longitudinal.[47]   
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 Case study research is distinct from case study teaching.  Though in the past, 
case study research was disparaged by some as “soft science” or quasi-
experimental, views have evolved and the current literature provides a clear 
methodology and rationale for its use.[47]  Strategies can be employed to address 
historical concerns such as: lack of rigor; ungeneralizable results; lengthy processes 
that produce expansive documents; and inability to establish causal 
relationships.[47]  Three key principles for data collection are suggested in 
consideration of construct validity and reliability: use multiple sources of evidence, 
create a case study database, and maintain a chain of evidence.[47]  To strengthen 
case study analysis, Yin proffers four general strategies: rely on theoretical 
propositions, develop a case study description, use both qualitative and quantitative 
data, and examine rival explanations.[47]  These strategies can be incorporated into 
several techniques for analysis such as pattern matching, explanation building, time-
series analysis, logic models, and cross-case synthesis.[47]   
More than other forms of research, case studies have the potential to reach 
multiple audiences.  It is suggested that case study reports account for this and, to 
the extent possible, prospective audiences for the report be identified prior to 
conducting the research. 
Discussion and Conclusions 
 Case study methods can be a good choice for research that seeks to answer 
“why” or “how” questions, such as how AI can be used to increase clinical trials 
efficiency?  The literature on case study design provides guidance for addressing 
essential issues of construct validity, internal validity, external validity, and reliability 
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that can be applied as appropriate to the proposed research.  Case study analysis 
benefits from theoretical propositions, which AI can provide in this case.   
 A multiple case study (i.e., including more than one cancer center) is beyond 
the scope of this dissertation; this research met several criteria for using a single 
case design.  The UNC Lineberger is representative of university-based matrix 
cancer centers, the application of AI with the UNC Lineberger’s CPO represents a 
unique test of AI theory, and it may serve as a revelatory case.  Case study 
methodology was followed in designing the research plan.  
V. Implications for Future Research 
The fact that no cancer center in the United States has been able to respond 
adequately to the recommendations of major national reports on increasing clinical 
trials efficiency underscores the need for innovative change.  From this literature 
review it can be induced that innovative approaches are needed to improve the 
efficiency of the clinical trials enterprise; that OD encompasses much of the 
expertise and strategy suggested for use in addressing intractable problems with the 
clinical trials system; that the outcomes of previous applications and AI principles 
suggest that it is a form of OD well suited to this purpose; and that case study 
research is an appropriate design for the proposed research.   
In 2006, Havens et al. wrote that the effectiveness of AI in healthcare 
remained largely untested and Bushe noted in 2010 that none of the published 
cases of AI took contextual variables into account.[41, 48]  AI has been applied 
successfully in healthcare organizations, particularly with nurses (who are central to 
clinical trials), but not in institutions with context and interpersonal dynamics directly 
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comparable to those of cancer centers.  This study is needed to describe if and how 
AI can be used under these circumstances and with what outcomes.  
Case study research is appropriate when “the boundaries between 
phenomenon and context are not clearly evident” which is relevant to the application 
of AI.[47]  This case study seeks to contribute to the body of knowledge about the 
use of AI and reports on a test of a potential solution to an important and intractable 
systems problem that needs solving.  
   
 
Chapter 3: Methods and Case Study Protocol  
A descriptive case research study was designed to better understand how AI 
can be used to improve the efficiency of cancer clinical trials.  Qualitative data from a 
single case, the UNC Lineberger, was used because of the potential for this case to 
be both revelatory and typical; the investigator had unique access to this center, AI 
has not been applied at other cancer centers, and the UNC Lineberger is 
comparable to other university-based cancer centers.  So that multiple sources of 
evidence could be used, two units of analysis were embedded into the single case.  
AI theory was used to define the scope of the case and the domain to which the 
case study’s findings could be analytically generalized.  A case study protocol and a 
case study database were developed. 
Case Study Description  
Propositions and Descriptive Theory. The propositions of this research 
were that AI could be applied with the UNC Lineberger’s CPO and that doing so 
would directly and indirectly lead to improvements in clinical trials efficiency.  Direct 
improvements may result from implementing ideas garnered through document 
review or interviews.  Indirect improvements may result from the positive effects of 
AI on the CPO, such as higher morale, better retention, a shared vision, or better 
communication. 
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The scope and depth of the case study were derived from the theory and 
principles of AI and from the needs of the institution.  As a descriptive study, this 
case did not seek to establish a causal relationship between the use of AI and 
improvements in efficiency; rather it sought to observe and describe how AI might be 
used to facilitate development of a better clinical trials system.  
Units of Analysis.  A single-case with two embedded units of analysis was 
designed.  The UNC Lineberger constituted the case because access and 
opportunity to apply AI were attainable.  The units of analysis were the CPO’s 
research coordinators and its disease team leaders.  The CPO’s research 
coordinators were included because of a pressing need to use a generative form of 
inquiry to learn more about how to improve their recruitment and retention; continuity 
of research coordinator employment directly impacts efficiency.  Evidence for this 
unit of analysis was obtained from documentation and participant observation 
The CPO’s disease team leaders were selected as the second unit of 
analysis because as the individuals who set trial priorities and provide medical 
leadership for teams, their work also has direct impact on efficiency.  Additionally, 
the disease team leaders are more likely to be knowledgeable about national efforts 
to improve efficiency which could generate ideas for efficiency improvements at 
UNC.  Evidence for this unit of analysis was obtained from interviews and 
participant-observation. 
Buy-in from the research coordinators and the disease team leaders would be 
essential to any future applications of AI, so an understanding of whether they are 
receptive to its use and how they respond is needed.   
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Case Study Protocol 
Unit of Analysis 1: Research Coordinators.  
Permission was obtained from the UNC Lineberger’s Clinical Research 
Leadership Team (CRLT) for the use documentation on file regarding an AI process 
improvement initiative conducted with the CPO’s research coordinators.  In reaction 
to a steep increase in resignations in early 2011, the Director of the UNC Lineberger 
tasked two members of the CRLT, the outgoing CPO Medical Director and the 
Cancer Center Assistant Director, with interviewing the research coordinators.  
Though charged with gaining an understanding of reasons for the turnover, the 
interview team felt that identifying potential solutions was essential.  It was also 
desirable for the inquiry process to contribute positively to morale rather than 
insinuate blame.  These factors, combined with an aspiration to bring about positive 
change in real-time, led the team to select AI as the format for the interviews. 
Email invitations were sent to fourteen research coordinators (see Appendix 
1).  A semi-structured AI interview guide (see Appendix 2) was constructed and pilot 
tested.  Research coordinators who were no longer employed at UNC by the time of 
the interviews or responded that they did not have time to participate in an interview 
were provided with the interview guide questions and invited to submit written 
responses.  Ten research coordinators participated in the initiative, including three 
who had recently or would soon resign.  A report describing the process and themes 
ascertained from the interviews was presented to the CRLT.  Subsequent discussion 
and actions were documented.   
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Unit of Analysis 2: Disease Team leaders. 
A modified version of the 4-D cycle of AI was applied with the disease team 
leaders.  Disease team leaders were identified by the CPO Medical Director (n=6) 
for inclusion in the second unit of analysis.  Invitations and a description of the study 
were sent by email (see Appendix 3). Interviews were conducted over a three week 
period in January 2012.  
A semi-structured interview guide was constructed (see Appendix 4) and pilot 
tested. Participants were provided with information about the study in the invitational 
email and given the opportunity to ask questions prior scheduling an interview.  
Appointments for interviews were made in advance and held in private offices.   
Verbal consent to participate was confirmed prior to any data collection.  
Consent for collection of detailed field notes during the interviews was also 
confirmed with participants.  Notes were subsequently typed up and stored securely 
under password protection.  Analysis of the AI interview data was conducted by 
visually identifying and tallying themes from the interview notes.  The most 
commonly cited themes were converted into provocative propositions.  Subsequent 
discussion and actions were documented. 
Case Study Protocol Questions 
The case study protocol for both groups included the following questions  
From analysis of AI report or interview documents: 
1. What themes were identified from the interviews? 
2. What provocative propositions were created from the themes? 
3. To what extent was the AI cycle applied with this group? 
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Participant observation 
4. What changes were observed during or since the interviews that could be 
attributed to the use of AI? 
5. In what ways was the use of AI with group effective towards the goal of 
improving clinical trials efficiency? 
6. What were the limitations, barriers, or obstacles to the use of AI with this 
group? 
IRB Review and Approval 
This study involved direct contact with human subjects so application was 
filed with the Public Health-Nursing IRB.  The submission was reviewed by the 
Office of Human Research Ethics and determined to be exempt from further review 
(i.e., “exempt from continuing review”).  All interviews were conducted in confidential 
settings and all field notes were stored under password protection on an encrypted 
computer.  Written consent was not required; verbal consent was obtained from the 
disease group leaders. 
Limitations and Opportunities 
The interactive and humanistic nature of research such as this case study 
requires the investigator to build rapport and credibility with the participants.  The 
degree to which this occurs may vary by participant and may impact the data that is 
collected.  Though an interview guide was used, follow up questions were adapted 
to the responses of the participants and were, consequently, not uniform.  
Responses may have been limited by concerns about expressing negative 
information about the CPO or the UNC Lineberger.  The selection of themes from 
the interview notes was subject to bias but validated by a second reader. 
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An important limitation of all action research described in the OD literature is 
that outcomes of action research studies should not be expected to be reproducible 
without a thorough consideration of the context.  The case study protocol provides a 
certain degree of reliability should future researchers desire to undertake a similar 
case study.  In terms of external validity, this case study seeks to generate 
knowledge about the use of AI in a university-based cancer center and may be 
analytically generalizable to the extent the context is taken into account.  An 
advantage of using AI for action research is that it is designed to adapt and account 
for the uniqueness of each organization.  The principles and techniques used in this 
case study may be applied elsewhere and the results can inform future AI initiatives 
at UNC and other cancer centers.   
   
 
Chapter 4: Results 
This chapter describes the results of a case study that was designed to better 
understand how AI can be used to improve clinical trials efficiency.  AI was applied 
with research coordinators and disease team leaders at the UNC Lineberger and 
case study protocol questions were addressed using document analysis and 
participant observation as follows:   
Research coordinators: Questions 1 and 2 were answered through analysis of 
documentation from a process improvement initiative (described below and in 
Chapter 3).  Questions 4 and 5 were answered through participant 
observation.  Questions 3 and 6 drew on both. 
Disease team leaders: Questions 1 and 2 were answered through primary 
analysis of interview notes.  Question 3 was answered using interview notes 
with additional information from participant observation. Questions 4, 5, and 6 
were answered through participant observation. 
A brief introduction, including rationale for inclusion and topic selection, is provided 
for each group followed by findings. 
I. Case Study Protocol: Research Coordinators 
Introduction 
A process improvement initiative using AI with the CPO’s research 
coordinators was conducted in June 2011.  An increase in turn-over had prompted a 
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request from the CRLT that the research coordinators be interviewed and AI was 
selected as the format for the interviews based on: an interest in shifting away from 
deficit-based problem solving; a need to think outside the box to find solutions; and a 
sense that appreciating what had worked well in the CPO would be beneficial.   
The AI topic was constructed by reframing the most pressing concern about 
turnover as a generative topic: fantastic research coordinators shepherding the best 
clinical trials in the US.  The interviews focused on how best to recruit and retain 
outstanding research coordinators, an essential factor in the efficient conduct of 
clinical trials.  The selection and recruitment processes are described in Chapter 3.  
Topics mentioned in the interviews by two or more research coordinators were 
included as themes.  No theme was mentioned by all 10 participants. 
Results from document review (report on AI process improvement initiative) 
1. What themes were identified from the interviews? 
Research coordinators would like to see: 
• better training for new nurses 
• that they are located with each other and near the cancer hospital  
• sanctioned flexibility about hours and schedules  
• more competitive salaries and opportunities to increase take-home pay.   
• more recognition 
• career ladders 
• use of workload metrics  
• a more supportive culture 
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2. What provocative propositions were created from the themes? 
1. Research coordinators receive orientation from colleagues who are actively 
enrolling patients and are knowledgeable about logistical details.  Other 
relatively new coordinators share their experiences to smooth and shorten the 
learning curve.  A checklist is used so that new coordinators and their 
colleagues feel confident they are well prepared for the challenges of being 
research coordinators and are cognizant of the differences between research 
nursing and floor nursing.  All coordinators are part of a supportive team.  
2. Research coordinators are located together in close proximity to their patients  
in the NC Cancer Hospital, facilitating support, information exchange, and  
cross-coverage.  Coordinators meet as needed with members of their team who, 
due to less frequent patient contact, are in other locations.  
3. Workload metrics and staff input are used iteratively and transparently in 
making work assignments.  Research coordinators customize their schedules 
to optimize performance and meet the needs of their trials and their work 
teams.  Research coordinators may work overtime when necessary to cross-
cover while positions are being filled.  Each week, time is included for 
“downtime” aka paperwork and organizing so that trials run smoothly.  
Research coordinators participate in meetings focused on issues of 
relevance.  Research coordinators receive recognition of superlative work in 
the form of raises when possible but through a wide range of other 
mechanisms on a consistent, on-going basis.  
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4. A career ladder enables research coordinators to strive and grow (whether HR-
official or designed internally).  New responsibilities are assumed as experience 
and knowledge increases.  Mentoring and career development conversations 
are provided regularly by other members of the CPO. 
5. The whole organization fosters and operates through open communication 
and teamwork at all levels (investigators, management, nurses etc.).  CPO 
management is receptive and responsive to input.  Silos across groups are 
made irrelevant by shared goals and collaborative operations. 
3.  To what extent was the AI cycle applied with this group? 
 The research coordinators participated in the Discovery phase of AI through 
interview questions that comprised the process improvement initiative.  Stories about 
the best of “what is” were shared in response to interview questions about peak 
times.  The documentation provided to the CRLT included high points mentioned by 
more than one participant: their interactions with physicians; coordinator’s 
relationships with patients; the pride they feel for the institution; and opportunities to 
learn, especially about the science of cancer.  Whether the research coordinators 
shared their high points with each other informally after the interviews is unknown. 
The Dream phase was initiated by asking questions about “what might be” 
with a standard AI question customized to the CPO (“We could all use more rest, so 
let’s say we have a great sleep that last for 10 years.  You wake up to find the CPO 
is everything you ever dreamed of.  What does that look like?”). 
For the Design phase, the sense-making (analyzing the stories) and 
generation of provocative propositions were conducted by the interview team not by 
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the participants. These propositions were shared with the CRLT but have not yet 
been shared with the research coordinators.  Research coordinators have not 
officially participated in the Destiny phase, though some steps have been taken to 
implement pieces of the propositions.  Both the Design and Destiny phases could be 
continued as part of the plan for change, following presentation of the results. 
Results from participant observation 
4.  What changes were observed during or since the interviews that could be 
attributed to the use of AI? 
Several major administrative changes were made by the CRLT immediately 
after receiving a report from the interviews with the themes and provocative 
propositions.  In particular, major management changes were made, corresponding 
to provocative proposition #5 (would like to see more receptive and responsive 
managers) and announced at a “town hall” meeting to which the entire CPO was 
invited.  The facility director was reassigned and a nurse management group was 
established.  A new medical director was appointed (position had been vacant) with 
authority to make change that had not been given to previous medical directors.  
CPO staff were encouraged to share input and numerous suggestions were received.   
After the town hall, a meeting was held with a core group of research 
coordinators and clinical research associates (CRAs) to begin a group discussion.  
At this meeting, it was reported that morale among the research coordinators had 
improved as a result of the AI interviews and that turnover had slowed.  The group 
expressed general optimism that things had taken a turn for the better.  A pair of 
research coordinators volunteered to draft a proposal outlining parameters for 
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flexible work hours (part of provocative proposition #3) and a collaboration between 
two nurses had been initiated to work on changing the orientation process for new 
research coordinators (part of provocative proposition #1).  
Through numerous discussions with senior research coordinators, the first 
part of provocative proposition #2 was implemented: the majority of the research 
coordinators were co-located in the NC Cancer Hospital by the end of 2011.  
Discussions were initiated about how to enact the second part of proposition #2 
(meet as needed with members of the team in other locations) and are ongoing.  
For proposition #3, administrative changes were made so research 
coordinators could be paid overtime (they could only accrue comp time previously).  
Efforts are ongoing to shift responsibility for assigning trials from a single manager to 
a group of senior research coordinators, with input from the disease team leaders.  
Effort tracking software was purchased and planning for implementation was begun. 
5.  In what ways was the use of AI with this group effective towards the goal 
of improving clinical trials efficiency? 
 The propositions generated through the AI process led to several actions that 
could increase efficiency in the long run, including better training for new research 
coordinators and relocation of the research coordinators to the NC Cancer Hospital.  
Implementation of additional items from the provocative propositions is underway 
(i.e., flexible hours) and members of an advisory team of senior coordinators 
reported that optimism was high.  No research coordinators have resigned since the 
AI interviews. Improved morale among the research coordinators could have a 
secondary effect on improving clinical trials efficiency, both by preventing turnover 
and by improving interactions.   
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6.  What were the limitations, barriers, or obstacles to the use of AI with this 
group? 
The documentation noted that majority of research coordinators (10 out of 15) 
were willing to participate in AI interviews, suggesting they were open to engaging in 
its use.  However, the extent of the effect was limited by the fact that the research 
coordinators were only minimally empowered to make changes; a system-wide AI 
initiative with the necessary stakeholder support could lead to greater impact.   
II. Case Study Protocol: Disease Team Leaders 
Introduction 
The CPO’s disease team leaders were selected for inclusion in this research 
about how AI might be used to improve clinical trials efficiency because they design 
trials, set trial priorities, and provide medical leadership for the disease teams, all of 
which are key to efficiency.  The disease team leaders would be key stakeholders in 
deciding whether to undertake a system-wide AI initiative, so understanding whether 
they are receptive to its use and how they might respond was needed.   
The AI topic for this group was constructed by reframing the overarching 
question at issue: building on what works well to make the CPO one of the most 
efficient clinical trials organizations in the country.  The primary focus of the disease 
team leader interviews was the circumstances under which clinical trials run most 
efficiently.  Additionally, an emerging issue about how best to organize staff in the 
disease teams prompted addition of a question as a sub-focus.  Procedures for 
selection and recruitment of participants are described in Chapter 3. Topics that 
were mentioned by three or more disease team leaders were included as themes.  
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Three themes were mentioned by all six disease team leaders. 
Results from document analysis (interview notes) 
1.  What themes were identified from the interviews? 
Disease team leaders would like to see: 
• exciting trials with interesting science that are opened and completed quickly 
• a good safety record; issues found early 
• high quality, clean data with no errors ready for use by investigators 
• clarity about roles and expectations for all personnel (faculty leaders, staff) 
• well trained and mentored staff who enjoy their work and have adequate 
control over workload to perform well 
• a central office that handles some administration but a strong sense that the 
disease groups are teams; staff are accountable to disease team leaders  
• transparency of CPO systems, operations and structure especially work 
assignments and workload determination 
• assistance writing papers; reduced time from activation to publication 
2.  What provocative propositions were created from the themes? 
1. UNC Lineberger concentrates its efforts on novel, interesting trials with 
exciting science.  High levels of energy and enthusiasm contribute to opening 
and completing these trials quickly. 
2. The safety record of trials managed by the CPO is impeccable.  Any safety 
issues are identified early and trials are conducted with no errors. 
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3. Excellent data management produces data that are clean and tight.  Data 
quality is monitored and anomalies are corrected quickly.  Time from trial 
initiation to publication of results is minimized because data are provided to 
investigators in a useable format.  Biostatistics personnel are actively involved 
and writing assistance is available. 
4. Centralized CPO systems and processes are transparent and clearly articulated.  
Information describing procedures, policies, and structure (what are pods, 
POEC) is distributed on a regular basis, especially to new investigators.   
5. Disease groups are cohesive teams.  Research staff are responsible to 
disease team leaders, who have access to workload metrics in facilitate 
assignment of work to their team members. 
6. Everyone involved with the CPO – disease team leaders, investigators, 
managers, research coordinators, coordinator assistants CRAs – knows what 
is expected of them and what they can expect of each other.  Roles are 
clearly defined even if there is variation between individuals holding similar 
roles on different disease teams.  
7. Research staff are well trained and mentored.  They have enough control over 
their workload that they are able to do a good job and be satisfied with their 
work.  The work environment is pleasant; faculty and staff at all levels are 
cooperative and collaborative. 
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Results from document review and participant observation 
3.  To what extent was the AI cycle applied with this group? 
By responding to the interview questions, the disease team leaders 
completed the Discovery phase of AI.  All participants recalled multiple trials 
(identified by trial number) that ran smoothly and efficiently.  “Peak times” occurred 
most often when a high level of enthusiasm about the science was present and 
when the trial was a high priority for both UNC and for the sponsor.  Some 
participants recalled high points when trials were planned well in advance at UNC 
and when a cohesive team was involved.  These high points will be shared through 
presentation of the case study to the Protocol Office Executive Committee (POEC).  
It is not known if the disease team leaders have shared highlights with each other. 
The “overheard question” served as a first step of the Dream phase.  In many 
cases it was necessary for the interviewer to follow the scripted question (“you 
overhear a fellow disease team leader telling a clinical trialist from another institution 
about our clinical trials office, what do you want to hear him say?”) with clarification 
that the question pertained to an imagined a future where the CPO was functioning 
well.  The “three wishes” question was met with mixed response.  Some participants 
had responded to the overheard question with the equivalent of three wishes and 
others found the question too abstract (i.e., did not find wishing for change to be a 
useful exercise).  Though most were able to think of either a simple step that could 
be taken, a bold step or both, some found these questions a bit perplexing.   
For the Design phase, the sense-making (analyzing the stories) and 
generation of provocative propositions were conducted by the interviewer not by the 
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participants.  The Design phase will be continued as part of the plan for change.  
Several concrete ideas about how to configure the disease teams were elicited from 
the pertinent question and could be a focus of discussion following the presentation 
of the case study.  Suggestions elicited in response to the small steps and bold 
ideas questions that did not constitute themes (mentioned by only one participant) 
could also be included in the presentation.  The Destiny phase may be initiated as 
part of the plan for change depending on the outcomes of the presentation. 
Results from participant observation 
4.  What changes were observed during or since the interviews that could be 
attributed to the use of AI? 
Several ideas described in the interviews (including two bold steps) were 
overheard in conversations or meetings in the week following the interviews.  In at 
least two instances, the statement was made by a non-participant who had recently 
interacted with the participant who suggested it.  Some of the provocative 
propositions may be implemented; most will take a substantial time to be realized.  
These changes will be tracked in the plan for change. 
5.  In what ways was the use of AI with this group effective towards the goal 
of improving clinical trials efficiency? 
Several provocative propositions were generated that, if implemented, could 
improve clinical trials efficiency.  By aggregating the opinions of the disease team 
leaders, their collective request for changes with the potential to improve efficiency 
may carry more weight with stakeholders.   
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Because the disease team leaders are empowered to make changes within 
their own teams, participation in the inquiry may prompt small positive changes that 
could lead to greater efficiency and which might then be shared with other teams.  
Asking the disease team leaders to imagine a preferred future may generate 
additional ideas in the future.  The interviews concluded with a statement that people 
who participate in AI sometimes find the questions spark ideas after the interviews.  
Participants were asked to contact the interviewer should this occur. 
6.  What were the limitations, barriers, or obstacles to the use of AI with this 
group? 
All of the disease team leaders agreed to participate and were engaged by 
the opportunity to provide information that might help improve efficiency.  However, 
conducting appreciative interviews using the topic of improved efficiency with the 
disease team leaders proved more challenging than using the topic of recruitment 
and retention with the research coordinators.  The efficiency topic, though relevant 
and important, was less personal and more abstract.  AI prompts consideration of 
whether the right questions are being asked and, if the disease team leaders had 
selected the topic as a group themselves, perhaps they might have chosen a more 
tangible or smaller-scale question to address first.   
The degree to which the disease team leaders were able to envision a 
positive future seemed to vary.  As anticipated from the literature, some physician 
participants found the positive focus foreign.  The majority of the responses could be 
framed as things they would “like to see more of” rather than deficits that needed 
fixing but seeing past the deficits to a preferred future was not simple. 
   
 
Chapter 5: Plan for Change 
As stated in Chapter 1, this case study was designed to investigate how 
appreciative inquiry can be used to improve clinical trials efficiency and to deliver a 
case study report on a trial application of AI at the UNC Lineberger Comprehensive 
Cancer Center.  This plan puts forward six recommendations to advance and sustain 
change towards creating a more efficient cancer clinical trials system.   
Recommendation 1: Present case study report to the POEC  
 Presentation of the process and findings of the case study will be made to the 
POEC (comprised of the disease team leaders and other cancer center leaders).  
POEC is an open meeting and other members of the CPO can be invited to attend, 
especially the research coordinator participants.  A discussion will be facilitated 
about whether the provocative propositions can be used to design an action plan (AI 
Design phase); whether additional ideas about improving efficiency have been 
generated since completion of the interviews; or whether an alternative approach to 
guiding the change process can be envisioned.  The members of the POEC are the 
key stakeholders for future change efforts in the CPO and would decide whether to 
proceed with more extensive (e.g., whole-system) AI initiatives to improve efficiency.  
If so, a steering committee comprised of representatives from various CPO groups 
would be assembled and charged with implementing Recommendation 2.  
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Recommendation 2: Initiate system-wide application of AI with the CPO. 
As outlined in Chapter 2, AI is predicated on the idea that organizations move 
towards what they study.  The steering committee representing all members of the 
CPO would be responsible for selecting the affirmative topic choice and designing 
the scope of the initiative.  Key issues to resolve with cancer center leaders when 
defining the scope will include cost and establishing boundaries for potential change 
(i.e., what the group is not empowered to change).  The results of this case study 
can contribute to initial topic discussions; concerns identified by this research such 
as the composition of and roles in disease teams or the organizational structure of 
the CPO (i.e., what functions should be centralized and what should be managed by 
the disease teams) will be suggested as possible areas of inquiry, though the 
steering committee will define the topic.  Relevant concepts in leadership theory and 
practice (see Recommendation 6 below) should guide this change effort.  
Recommendation 3: Monitor efficiency metrics and assess impact of AI 
This case study report describes how AI was used with the CPO and the 
extent to which it had a proximal impact on clinical trials efficiency.  Downstream 
effects on time-to-activation and percentage of trials meeting accrual goals will be 
measured over the subsequent 12-18 months.  As described in the literature review, 
quantitative data on these measures is being captured by members of UNC’s RaPID 
team.  If improvements in these metric are observed, qualitative data will be 
obtained to assess the contributions of AI to the improvement.  Follow-up interviews 
can be designed and conducted with research coordinators and disease team 
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leaders (and other participants if a system-wide initiative occurs) to assess changes 
attributable to the use of AI. 
Recommendation 4: Assess other potential AI applications at UNC Lineberger 
Applying concepts from leadership theory and practice (see Recommendation 
6), key stakeholders will be identified and invited to consider other potential change 
efforts that would benefit the UNC Lineberger, including the use of AI with other 
groups.  For example, UNC Lineberger’s Program Planning Committee (PPC) is 
comprised by leaders of the 10 programs of cancer research but expectations of the 
programs and their leaders are not clear.  With significant growth of the UNC 
Lineberger in recent years, including faculty additions, the programs have an 
opportunity to play a larger role in setting scientific directions, mentoring young 
faculty, and supporting collaborations within and between programs.  A number of 
topics could potentially be selected for an AI initiative with the programs and leaders.  
Members of the PPC could potentially serve as a topic selection steering committee.   
Jacqueline Stavros and others have demonstrated that in some cases where 
stakeholders are not familiar with AI, or perhaps less amenable to it, a positive 
approach to change is more easily adopted if it is first introduced as the SOAR 
(strengths, opportunities, aspirations, and results) model.[49]  SOAR is a positive 
approach to strategic thinking used in place of the SWOT (strengths, weakness, 
opportunities, and threats) model, with which most cancer center faculty are familiar.  
Other leadership concepts, which are relevant to strategic planning and may be 
employed to bring about change at the UNC Lineberger, are described in 
Recommendation 6.  
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Recommendation 5: Publish and present findings  
Findings will be disseminated as appropriate to cancer clinical trials 
organizations, the cancer research community, AI practitioners, and the field of OD 
through publications or presentations.  The AI Commons invites doctoral students to 
post completed dissertations that used AI on their website.  The journal, AI 
Practitioner, publishes on the use of AI as does the Journal of Applied Behavior 
Sciences, the source for numerous articles in the literature review for this 
dissertation.  The Association of American Cancer Institutes has a Clinical Research 
Initiative group that meets regularly.  The users group of the OnCore database, a 
data management system for cancer clinical trials, holds national meetings twice a 
year and invites presentations on relevant issues such as efficiency.   
Recommendation 6: Apply and disseminate leadership theory and practice 
Applications of leadership theory and practice can significantly contribute to 
improving the cancer clinical trials system at UNC and elsewhere.  Though many 
leadership concepts could support the change effort with the CPO, several specific 
examples are provided as part of this recommendation. 
Starting with the POEC, a guiding coalition will be built, tracking with the 
advice of John P. Kotter:  the right people need to be involved, including individuals 
who have strong position power, high credibility, and leadership skills.[50]  Kotter 
entreats leaders to develop a vision and strategy, communicate the change vision, 
empower employees for broad-based action, and generate short-term wins.[50]  On 
numerous occasions, the UNC Lineberger’s leadership team has discussed the 
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need to create a mission statement and a shared vision for the CPO.  The practices 
that comprise Kotter’s action plan for leading change can facilitate this process. 
In his plenary address, Escape Fire: Lessons for the Future of Health Care, 
Don Berwick’s ties together several sources of leadership advice, including that of 
Karl Weick who Berwick considers a student of organizations under stress 
(characteristic of the CPO).[51]  A central function of organizations is sensemaking, 
the process through which order is created and “people can orient themselves, find 
purpose, and take effective action.”[52]  Berwick recounts Weick’s story of a group of 
soldiers who, desperate to find their way out of the Alps, find and use a map to 
successfully guide themselves out, only to realize later it was a map of the 
Pyrenees.  From this Weick points out that part of the value of sensemaking is that 
sometimes “when you are lost, any map will do.” [51]  Whether sensemaking in the 
CPO is accomplished using the phases of AI or another mechanism, caution should 
be used as staff roles are redefined.  Berwick related this “recipe” for the collapse of 
sensemaking from Weick: 
Thrust people into unfamiliar roles; leave some roles unfilled; make the task 
more ambiguous; discredit the role system; and make all of these changes in 
a context in which small things can combine into something monstrous.[51] 
Berwick also shared an applicable personal lesson, noting that he experienced that 
in a hospital, “the people work well, by and large, but the system often does not.”[51]  
The CPO has many hard working individuals but systems that may not.  A systems 
view, and changes to systems, will be needed to advance change in the CPO. 
 The CPO could benefit from becoming what Weick and Sutcliffe deem a “high 
reliability organization.”  In a high reliability organization, a mindful infrastructure 
tracks small failures; resists oversimplification; remains sensitive to operations; 
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maintains capabilities for resilience; and takes advantage of shifting locations of 
expertise.[5353] If the CPO were to become a high reliability organization, it would 
have greater capacity to manage unexpected events that threaten its efficiency. 
There are many other leadership lessons and tips that can benefit the CPO 
and its personnel.  Disease teams rely on lower-level staff to ensure necessary 
steps are taken.  To facilitate important information exchange processes, these 
individuals are often called upon to lead people over whom they have no control.  
The CPO encompasses individuals with many competing interests and priorities.  To 
lead the organization through its many inevitable conflicts, mediation tools are 
needed to transform that conflict into opportunity.  
Conclusion  
Finding better treatments for cancer is a global priority.  Academic medical 
centers like the UNC Lineberger make unique contributions to the nation’s cancer 
clinical trials program.  Innovative approaches to improving the efficiency of clinical 
trials are needed.  This case study describes how AI was applied with two key 
groups within the UNC Lineberger’s clinical trials organization, demonstrating that 
receptivity and responsiveness to AI can be found in such an organization and that 
application of AI with these groups can generate ideas that may lead to improved 
efficiency. Further research is needed to establish a causal relationship between 
applications of AI and improvements in efficiency.  This work also demonstrates that 
continued applications of leadership theory and practice, including strategic planning 
and organization development techniques, can contribute to the advancement of 
efforts to develop better treatments for cancer. 
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Appendix 1: Email Invitation to Research Coordinators 
 
The CPO is the largest core in the Cancer center and critical to the LCCC mission.  
The clinical trials efforts have been very successful over the past few years. Accrual 
reached over 1000 pts on therapeutic trials this year.  Important trials have been 
presented at national meetings and published in top journals.  Our cancer center 
core grant was rated outstanding by the NCI. The cancer center leadership is very 
proud of the CPO. However, we are all worried about the nursing shortage. We are 
soon to be operating with only 11 nurses, which is down 30% from our planned staff 
capacity.  
Dr Earp has asked Wendy Sarratt (Assistant Director at LCCC) and me to interview 
all the CPO nurses to get some perspective on the potential reasons for the nursing 
shortage and how we can improve hiring and retention of top quality research 
coordinators like you.   We are interested in talking to you about what is working well 
and how we can make things better. All of your answers will be confidential and will 
not be reported individually, only in aggregate.  
We hope you will be willing to help us in this process. Are you free to talk for 15 min 
later this week or next? If you are not comfortable talking, would you fill out a 5 
question questionnaire?  
Thanks, 
Claire Dees and Wendy Sarratt 
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Appendix 2: Research Coordinator Interview Guide 
1. Think back to when you decided to accept your position in the CPO.  What 
inspired you to say yes to coming here?  What keeps you here? 
2. Tell me about a high point for you during your time as a CPO nurse. 
3. If we were to ask people who know you well, what are the three best qualities 
or capabilities they would say that you bring to the CPO? 
4. If you had three wishes for yourself and your research coordinator colleagues, 
what would they be?  What would you like to see more of? 
5. Thinking about the CPO as a whole, what does it look like when it’s at its 
best? 
6. We could all use more rest, so let’s say we have a great sleep that last for 10 
years.  You wake up to find the CPO is everything you ever dreamed of.  
What does that look like? 
7. What is the simplest step we could take to make that dream a reality?  What 
is the boldest step you can think of? 
8. Anything else you want to share? 
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Appendix 3: Email Invitation to Disease Team Leaders  
Dear Disease Team Leaders, 
Some of you know that I am a candidate for a DrPH (doctorate of public health) from 
UNC’s executive doctoral program in health leadership.  I am interested in 
integrating my dissertation into our efforts to improve the efficiency of the CPO.  One 
piece of the data collection for my case study involves interviewing the pod leaders 
about your experience with the CPO, what works well, and what we might do to 
make it run more efficiently.   
I am writing to ask if you would be willing to participate in my research study.  If you 
are, can we schedule about 30 minutes to talk?  All of your answers will be 
confidential and will not be reported individually, only in aggregate.   Because there 
are a small number of you, there is a chance that your input might be discernible to 
your colleagues.  My dissertation committee has asked that I give a presentation of 
my results to the folks who are part of the case study, so I will hold a forum and 
invite the faculty and staff involved with the CPO to that.  If the presentation were to 
include information that had any chance of being linked back to you, I would let you 
review the slides before they are presented and make changes if necessary (the 
topics we might touch on in the interview are not sensitive information).  I am also 
hoping to publish results and would be happy to share drafts before they are 
submitted. 
Let me know if you have any questions about this and I look forward to speaking 
with you. 
Thanks, Wendy 
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Appendix 4: Disease Team Leaders Interview Guide 
As you know, our conversation today is part of a case study I’m doing for my 
dissertation research on clinical trials efficiency as part of a doctoral program in 
health leadership.  This study has been exempted from full review by the IRB and 
the email you received inviting you to participate covered issues related to 
confidentiality and reporting the results of the study.  Would you like me to go over 
those with you?  I’m going to read a brief introduction and then ask you six 
questions.  Is it OK if I write down your responses?  Do you have any questions 
before we get started?   
 
Clinical trials efficiency is a national concern that we share here at the UNC 
Lineberger.  There are numerous efforts underway nationally to try to improve the 
system, like our RaPID grant working on time to activation goals and the new 
scoring system we’ve started using in POEC to prioritize trials.  Even with the 
concerns we are trying to address, there are many things about the CPO that work 
well.  As we move ahead, we want to see if there ways we can build on what works 
well to move towards making our clinical trials organization the best in the country.   
1. Tell me about a time when a trial in your pod ran smoothly and efficiently?  
Who was involved?  What was different about that trial that made it stand out? 
2. You’re at a national meeting and you overhear one of your fellow disease 
team leaders telling a clinical trialist from another institution about our clinical 
trials office.  What would you want to hear him say? 
3. We’re currently in a state of transition with disease teams trying out new ways 
of assigning tasks and redefining roles.  If you could reconfigure your team 
any way you wanted, what would that look like? 
4. If you had three wishes for yourself and the CPO, what would they be?  What 
would you like to see more of? 
5. What is the simplest step we could take so that our CPO conducts trials more 
efficiently and successfully than you ever imagined it could?  What is the 
boldest step you can think of? 
6. Anything else you want to share? 
Thank you very much for your time.  I appreciate you sharing your thoughts with me 
on this topic, which will help both with our work to optimize the CPO and with my 
health leadership doctoral work.  I will be looking for themes across the interviews 
and then the POEC can talk as a group about how we might move forward.  Also, 
people who participate in appreciative inquiry sometimes find that the questions 
spark ideas after the interviews are over and if you think of other changes you’d like 
to see, please let me or Bert know.  Thanks again. 
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Appendix 5: List of Definitions 
ACCRUAL: The process of placing patients on trial; a patient on a trial.  . 
ACCRUAL GOAL: the number of patients sought for a clinical trial.   
ACCRUE: to enroll a patient on a trial.   
ACTIVATION/ACTIVATE: the point when patient enrollment on a trial may begin.  . 
CLINICAL: Pertaining to or founded on observation and treatment of participants, as 
distinguished from theoretical or basic science. 
CLINICAL INVESTIGATOR: A medical researcher in charge of carrying out a clinical 
trial's protocol.  
CLINICAL TRIALS: a research study to answer specific questions about new 
therapies or new ways of using known treatments. Clinical trials are used to 
determine whether new drugs or treatments are both safe and effective in four 
phases (see below)  
ENROLLING: The act of signing up participants for a study by evaluating whether 
they meet the eligibility criteria for the study and by going through the informed 
consent process. 
INVESTIGATIONAL NEW DRUG: A new drug, antibiotic drug, or biological drug that 
is used in a clinical investigation.  
NEW DRUG APPLICATION (NDA): An application submitted by the manufacturer of 
a drug to the FDA - after clinical trials have been completed - for a license to market 
the drug for a specified indication. 
OPEN: the point at which a protocol is available to patients    
PHASE I TRIALS: Initial studies to determine the metabolism and pharmacologic 
actions of drugs in humans, the side effects associated with increasing doses, and to 
gain early evidence of effectiveness; may include healthy participants and/or 
patients. 
PHASE II TRIALS: Controlled clinical studies conducted to evaluate the 
effectiveness of the drug for a particular indication or indications in patients with the 
disease or condition under study and to determine the common short-term side 
effects and risks.  
PHASE III TRIALS: Expanded controlled and uncontrolled trials after preliminary 
evidence suggesting effectiveness of the drug has been obtained, and are intended 
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to gather additional information to evaluate the overall benefit-risk relationship of the 
drug and provide an adequate basis for physician labeling.  
PHASE IV TRIALS: Post-marketing studies to delineate additional information 
including the drug's risks, benefits, and optimal use. 
PROTOCOL: A study plan on which all clinical trials are based. The plan is carefully 
designed to safeguard the health of the participants as well as answer specific 
research questions. A protocol describes what types of people may participate in the 
trial; the schedule of tests, procedures, medications, and dosages; and the length of 
the study. While in a clinical trial, participants following a protocol are seen regularly 
by the research staff to monitor their health and to determine the safety and 
effectiveness of their treatment. 
TARGETED ENROLLMENT: the number of patients needed for a trial (see also 
accrual goal). 
TREATMENT TRIALS: Refers to trials which test new treatments, new combinations 
of drugs, or new approaches to surgery or radiation therapy 
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